Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intralymphatic grass pollen immunotherapy for grass pollen allergic rhinitis
NL-OMON39544Phase 3Active, not recruiting
- Sponsor
- HagaZiekenhuis
- Start
- Nov 2011
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinitis (AR) and allergic rhinoconjunctivitis (ARC) comparing Alutard grass pollen intranodal immunotherapy with Placebo intranodal injection (2 arms). Primary endpoint: Primary study outcome measure. Started Nov 2011; status: active, not recruiting.
02
Drugs
Phleum pratense pollen extract
03
Conditions
allergic rhinitis (AR)allergic rhinoconjunctivitis (ARC)
Beyond the preview
Go deeper on NL-OMON39544.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39544.